- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03200366
Comparing Interventions to Increase Colorectal Cancer Screening
Comparing Interventions to Increase Colorectal Cancer Screening in Low-Income and Minority Patients
The purpose of this study is to test different approaches to help people understand the purpose of colorectal cancer (CRC) screening, two screening test options available, and the barriers to screening so they can make informed decisions about CRC screening. Participants will be randomly assigned to one of three groups: (1) one group will receive a tailored digital video disc (DVD) in the mail; (2) another group will receive the mailed DVD plus telephone calls from a patient navigator; and (3) the third group will receive the care normally provided by the healthcare system's endoscopy department.
The investigators hypothesize the following: (1) participants who receive the tailored DVD plus the patient navigation intervention will have higher rates of CRC screening with the fecal immunochemical test (FIT), colonoscopy, or either screening test compared to those who receive the tailored DVD alone; (2) participants who receive either intervention (DVD only or DVD plus patient navigation) will have higher rates of CRC screening with FIT, colonoscopy, or either screening test than those who receive usual care; and (3) participants who receive either intervention who complete colonoscopy will have better quality of bowel preparation, less anxiety about the procedure, and greater satisfaction with the colonoscopy experience than those who receive usual care.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Eskenazi Health
-
Indianapolis, Indiana, États-Unis, 46202
- Indiana University School of Nursing
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Referred for a screening colonoscopy that was not done (i.e, canceled or no show)
Exclusion Criteria:
- Unable to speak, read, and write English
- Personal history of CRC or polyps
- Personal history of conditions that place participants at high risk for CRC such as ulcerative colitis, Crohn's disease, or known hereditary syndromes such as familial adenomatous polyposis or hereditary nonpolyposis colorectal cancer
- Family history of CRC which increases the participant's risk for CRC
- Advised by a health care provider to not have a colonoscopy due to the participant's health
- Speech impairment
- Hearing impairment
- Cognitive impairment
- Vision impairment
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Dépistage
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur actif: Tailored DVD
Tailored digital video disc (DVD)
|
A 20 minute tailored DVD titled "Approaches to Colon Testing" is viewed by participants.
It is designed to encourage CRC screening uptake by colonoscopy or FIT by increasing the participant's CRC knowledge and beliefs about the benefits of screening, reducing barriers to screening, and increasing self-efficacy for screening by demonstrating how these tests are performed.
|
Comparateur actif: Tailored DVD + Patient Navigation
Tailored digital video disc (DVD) plus Patient Navigation by a population health nurse in the healthcare system
|
A 20 minute tailored DVD titled "Approaches to Colon Testing" is viewed by participants.
It is designed to encourage CRC screening uptake by colonoscopy or FIT by increasing the participant's CRC knowledge and beliefs about the benefits of screening, reducing barriers to screening, and increasing self-efficacy for screening by demonstrating how these tests are performed.
Participants talk by telephone with a Patient Navigator who is a trained nurse.
The Patient Navigator determines if participants viewed the tailored DVD and answers any questions about the content.
The Patient Navigator then provides telephone counseling on CRC and screening tests to: (1) increase knowledge, perceived benefits, and self-efficacy; (2) reduce barriers; (3) enhance access; and (4) provide social support.
|
Aucune intervention: Usual Care
Care normally provided by a nurse in the endoscopy department of the healthcare system
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Participants Completing CRC Screening Per Electronic Medical Record Documentation
Délai: 12 months post-baseline interview
|
Number of participants completing CRC screening by any test (defined as colonoscopy or FIT) is measured by electronic medical record review.
Dates that participants had a colonoscopy and dates of FIT analysis are extracted from the electronic medical record.
|
12 months post-baseline interview
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Participants Completing Colonoscopy Per Electronic Medical Record Documentation
Délai: 12 months post-baseline interview
|
Number of participants completing a colonoscopy is measured by electronic medical record review (EMR).
Dates that participants completed a colonoscopy are extracted from the EMR.
|
12 months post-baseline interview
|
Bowel Preparation Quality Rating Using Boston Bowel Preparation Scale
Délai: 12 months post-baseline interview
|
Participants quality of bowel preparation is measured by the endoscopist during their colonoscopy procedure using the Boston Bowel Preparation Scale (BBPS).
BBPS scores the total quality on a 10 point scale from 0-9.
Higher scores indicate better quality of bowel preparation.
|
12 months post-baseline interview
|
Participants With Adequate Quality of Bowel Preparation Per Modified Aronchick Rating Scale
Délai: 12 months post-baseline interview
|
Participants quality of bowel preparation is measured by the endoscopist during their colonoscopy using a modification of the Aronchick rating scale.
The Aronchick scale rates quality as 1=excellent, 2=good, 3=fair, or 4=poor.
Some endoscopists choose to grade quality more generally as adequate vs. inadequate.
To accommodate this variation, bowel preparation ratings have been dichotomized into adequate (excellent, good, fair, or adequate ratings) vs. inadequate (poor or inadequate ratings).
Adequate is scored as 1 and indicates better quality of bowel preparation than inadequate which is scored as 0.
|
12 months post-baseline interview
|
Colonoscopy-Related Procedural Anxiety for Participants Completing a Colonoscopy
Délai: 12 months post-baseline interview
|
Colonoscopy-related procedural anxiety is measured by self-report using the 6-item short form of the State Anxiety Scale of the State-Trait Anxiety Inventory.
Each item is scored from 1 to 4 (1=not at all; 4=very much so) with higher scores indicating greater anxiety.
|
12 months post-baseline interview
|
Satisfaction With Colonoscopy Experience
Délai: 12 months post-baseline interview
|
Satisfaction with the colonoscopy experience is measured by self-report using a single item developed by the research team.
Satisfaction is rated from 1 to 4 where 1=not at all satisfied, 2=a little satisfied, 3=mostly satisfied, and 4=completely satisfied.
Scores range from 1 to 4 with higher scores indicating greater satisfaction.
|
12 months post-baseline interview
|
Participants Completing a Fecal Immunochemical Test (FIT) Per Electronic Medical Record Documentation
Délai: 12 months post-baseline interview
|
Number of participants completing a FIT is measured by electronic medical record review (EMR).
Dates of FIT analysis are extracted from the EMR.
|
12 months post-baseline interview
|
Participants Who Self-Reported Completing CRC Screening
Délai: 6-9 months post-baseline interview
|
Number of participants who reported completing CRC screening by any test (defined as colonoscopy or FIT) during the 6 or 9 month post-baseline telephone interview.
|
6-9 months post-baseline interview
|
Participants Who Self-Reported Completing a Colonoscopy
Délai: 6-9 months post-baseline interview
|
Number of participants who reported completing a colonoscopy during the 6 or 9 month post-baseline telephone interview.
|
6-9 months post-baseline interview
|
Participants Who Self-Reported Completing a Fecal Immunochemical Test (FIT)
Délai: 6-9 months post-baseline interview
|
Number of participants who reported completing a FIT during the 6 or 9 month post-baseline telephone interview.
|
6-9 months post-baseline interview
|
Change in Knowledge of CRC and Screening
Délai: 6 months post-baseline interview
|
Change from baseline in knowledge of CRC and screening is measured at 6 months by self-report using a 9-item multidimensional scale.
Each item is scored as 1=correct or 0=incorrect and summed to yield a scale score.
Scores range from 0 to 9 with higher summated scores indicating greater knowledge of CRC and screening tests.
The mean of the 9 items is calculated at baseline and 6 months post-baseline.
Change from baseline equals the mean at 6 months minus the mean at baseline.
Change can range from -9 to 9 with positive values indicating an increase in knowledge.
|
6 months post-baseline interview
|
Change in Perceived Risk for CRC
Délai: 6 months post-baseline interview
|
Change from baseline in perceived risk for CRC is measured by self-report at 6 months using a 3-item scale.
We ask participants how likely it is that they will get colon cancer sometime during their lifetime, within the next 10 years, and within the next 5 years.
Each item is scored from 1 to 4 (1=very unlikely; 4=very likely).
Higher scores indicate a higher perceived risk for getting CRC.
The mean of the 3 items is calculated at baseline and 6 months.
Change in perceived risk equals the mean at 6 months minus the mean at baseline.
Change can range from -3 to 3 with positive values indicating an increase in perceived risk for getting CRC.
|
6 months post-baseline interview
|
Change in Colonoscopy-Related Procedural Anxiety Regardless of Whether or Not Participants Had a Colonoscopy
Délai: 6 months post-baseline interview
|
Change from baseline in colonoscopy-related procedural anxiety is measured at 6 months by self-report using the 6-item short form of the State Anxiety Scale of the State-Trait Anxiety Inventory.
Each item is scored from 1 to 4 (1=not at all; 4=very much so) with higher scores indicating greater anxiety.
The mean of the 6 items is calculated at baseline and 6 months post-baseline.
Change from baseline is the mean at 6 months minus the mean at baseline.
Change can range from -3 to 3 with positive values indicating an increase in anxiety.
|
6 months post-baseline interview
|
Change in Perceived Benefits of CRC Screening by Colonoscopy
Délai: 6 months post-baseline interview
|
Change from baseline in perceived benefits of CRC screening by colonoscopy is measured at 6 months by self-report using a 4-item scale.
Each item is scored from 1 to 4 (1=strongly disagree; 4=strongly agree) and the mean of the 4 items calculated.
Higher mean scores indicate greater perceived benefits of screening by colonoscopy.
Change in perceived benefits equals the mean at 6 months minus the mean at baseline.
Change can range from -3 to 3 with positive values indicating an increase in perceived benefits of screening by colonoscopy.
|
6 months post-baseline interview
|
Change in Perceived Barriers to CRC Screening by Colonoscopy
Délai: 6 months post-baseline interview
|
Change from baseline in perceived barriers to CRC screening by colonoscopy is measured at 6 months by self-report using a 16-item scale.
Each item is scored from 1 to 4 (1=strongly disagree; 4=strongly agree) and the mean of the 16 items calculated.
Higher mean scores indicate greater perceived barriers to screening by colonoscopy.
Change in perceived barriers equals the mean at 6 months minus the mean at baseline.
Change can range from -3 to 3 with negative values indicating a decrease in perceived barriers to screening by colonoscopy.
|
6 months post-baseline interview
|
Change in Perceived Self-Efficacy for CRC Screening by Colonoscopy
Délai: 6 months post-baseline interview
|
Change from baseline in perceived self-efficacy for colonoscopy is measured at 6 months by self-report using an 11-item scale.
Each item is scored from 1 to 4 (1=not at all sure; 4=very sure) and the mean of the 11 items calculated.
Higher mean scores indicate greater perceived self-efficacy for screening by colonoscopy.
Change in perceived self-efficacy equals the mean at 6 months minus the mean at baseline.
Change can range from -3 to 3 with positive values indicating an increase in perceived self-efficacy for screening by colonoscopy.
|
6 months post-baseline interview
|
Change in Perceived Benefits of CRC Screening by FIT
Délai: 6 months post-baseline interview
|
Change from baseline in perceived benefits of CRC screening by FIT is measured at 6 months by self-report using a 3-item scale.
Each item is scored from 1 to 4 (1=strongly disagree; 4=strongly agree) and the mean of the 3 items calculated.
Higher mean scores indicate greater perceived benefits of screening by FIT.
Change in perceived benefits equals the mean at 6 months minus the mean at baseline.
Change can range from -3 to 3 with positive values indicating an increase in perceived benefits for screening by FIT.
|
6 months post-baseline interview
|
Change in Perceived Barriers to CRC Screening by FIT
Délai: 6 months post-baseline interview
|
Change from baseline in perceived barriers to CRC screening by FIT is measured at 6 months by self-report using a 10-item scale.
Each item is scored from 1 to 4 (1=strongly disagree; 4=strongly agree) and the mean of the 10 items calculated.
Higher mean scores indicate greater perceived barriers to screening by FIT.
Change in perceived barriers equals the mean at 6 months minus the mean at baseline.
Change can range from -3 to 3 with negative values indicating a decrease in perceived barriers to screening by FIT.
|
6 months post-baseline interview
|
Change in Perceived Self-Efficacy for CRC Screening by FIT
Délai: 6 months post-baseline interview
|
Change from baseline in perceived self-efficacy for CRC screening by FIT is measured at 6 months by self-report using a 7-item scale.
Each item is scored from 1 to 4 (1=not at all sure; 4=very sure) and the mean of the 7 items calculated.
Higher mean scores indicate greater perceived self-efficacy for screening by FIT.
Change in perceived self-efficacy equals the mean at 6 months minus the mean at baseline.
Change can range from -3 to 3 with positive values indicating an increase in perceived self-efficacy for screening by FIT.
|
6 months post-baseline interview
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Susan M Rawl, PhD,RN, Indiana University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 1605880142
- IHS-1507-31333 (Autre subvention/numéro de financement: Patient-Centered Outcomes Research Institute (PCORI))
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Délai de partage IPD
Critères d'accès au partage IPD
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cancer colorectal
-
City of Hope Medical CenterRecrutementTumeurs colorectales | Cancer colorectal | Troubles colorectaux | Adénocarcinome colorectal | Cancer colorectal stade II | Cancer colorectal stade III | Cancer colorectal stade IV | Polype colorectal | Tumeurs colorectales malignes | Polype adénomateux colorectal | Cancer colorectal stade I | Adénome colorectal... et d'autres conditionsÉtats-Unis, Italie, Chine, Espagne, Japon
-
Docbot, Inc.RecrutementAdénome colorectal | Adénocarcinome colorectal | Polype colorectal | ASS colorectalÉtats-Unis
-
University of California, San FranciscoComplétéCancer colorectal de stade IV AJCC v8 | Cancer colorectal de stade IVA AJCC v8 | Cancer colorectal de stade IVB AJCC v8 | Cancer colorectal de stade IVC AJCC v8 | Cancer colorectal de stade III AJCC v8 | Cancer colorectal de stade IIIA AJCC v8 | Cancer colorectal de stade IIIB AJCC v8 | Cancer... et d'autres conditionsÉtats-Unis
-
University of Southern CaliforniaNational Cancer Institute (NCI)RésiliéCancer colorectal de stade IV AJCC v8 | Cancer colorectal de stade IVA AJCC v8 | Cancer colorectal de stade IVB AJCC v8 | Cancer colorectal de stade IVC AJCC v8 | Cancer colorectal de stade III AJCC v8 | Cancer colorectal de stade IIIA AJCC v8 | Cancer colorectal de stade IIIB AJCC v8 | Cancer... et d'autres conditionsÉtats-Unis
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Actif, ne recrute pasCancer colorectal métastatique | Adénocarcinome colorectal | Cancer colorectal de stade IV | Cancer colorectal de stade IVA | Cancer colorectal de stade IVB | Carcinome colorectal réfractaire | Carcinome colorectal stable microsatellite métastatique | Cancer colorectal de stade IVCÉtats-Unis
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Actif, ne recrute pasCancer colorectal de stade IV AJCC v8 | Cancer colorectal de stade IVA AJCC v8 | Cancer colorectal de stade IVB AJCC v8 | Cancer colorectal de stade IVC AJCC v8 | Cancer colorectal de stade III AJCC v8 | Cancer colorectal de stade IIIA AJCC v8 | Cancer colorectal de stade IIIB AJCC v8 | Cancer... et d'autres conditionsÉtats-Unis
-
M.D. Anderson Cancer CenterRecrutementAdénocarcinome colorectal | Cancer colorectal de stade IVA AJCC v8 | Cancer colorectal de stade IVB AJCC v8 | Cancer colorectal de stade IVC AJCC v8 | Cancer colorectal de stade III AJCC v8 | Cancer colorectal de stade IIIA AJCC v8 | Cancer colorectal de stade IIIB AJCC v8 | Cancer colorectal de... et d'autres conditionsÉtats-Unis
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)RésiliéCancer rectal | Cancer du colon | Survivant du cancer | Adénocarcinome colorectal | Cancer colorectal de stade III AJCC v8 | Cancer colorectal de stade IIIA AJCC v8 | Cancer colorectal de stade IIIB AJCC v8 | Cancer colorectal de stade IIIC AJCC v8 | Cancer colorectal de stade I AJCC v8 | Cancer colorectal... et d'autres conditionsÉtats-Unis
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActif, ne recrute pasAdénome colorectal | Cancer colorectal de stade III AJCC v8 | Cancer colorectal de stade IIIA AJCC v8 | Cancer colorectal de stade IIIB AJCC v8 | Cancer colorectal de stade IIIC AJCC v8 | Cancer colorectal de stade 0 AJCC v8 | Cancer colorectal de stade I AJCC v8 | Cancer colorectal de stade II... et d'autres conditionsÉtats-Unis
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCRetiréAdénocarcinome colorectal métastatique | Adénocarcinome colorectal réfractaire | Microsatellite Stable | Cancer colorectal de stade IV AJCC v8 | Cancer colorectal de stade IVA AJCC v8 | Cancer colorectal de stade IVB AJCC v8 | Cancer colorectal de stade IVC AJCC v8 | Cancer colorectal de stade... et d'autres conditionsÉtats-Unis
Essais cliniques sur Tailored DVD
-
The Miriam HospitalNational Institute of Mental Health (NIMH); Brown University; University of... et autres collaborateursComplétéInfections à VIH | Maladies sexuellement transmissibles | VIHÉtats-Unis
-
VA Office of Research and DevelopmentComplétéHypertensionÉtats-Unis
-
University of North Carolina, Chapel HillRetiréMaladie vasculaire intracrânienneÉtats-Unis
-
Case Comprehensive Cancer CenterAmerican Cancer Society, Inc.; Consumer Wellness Solutions; North Carolina Tobacco...Complété
-
The University of Hong KongThe Boys' and Girls' Clubs Association of Hong KongComplété
-
University of Texas Southwestern Medical CenterAgency for Healthcare Research and Quality (AHRQ)ComplétéTumeurs mammaires | Tumeurs pulmonaires | Tumeurs du côlonÉtats-Unis
-
University of RochesterThe Commonwealth Fund; Academic Pediatric AssociationComplété
-
Nova Scotia Health AuthorityCapital Health, CanadaComplétéMaladies pulmonairesCanada
-
IRCSS Istituto Dermopatico dell'Immacolata, Fondazione...Ministry of Health, Italy; Centro di Eccellenza per la Cultura e la Ricerca...Complété